We are thrilled to announce that the highly anticipated N-Nitroso impurities of Amide and Indole have now been successfully developed e.g. N-Nitroso Orlistat , N-Nitroso Ropinirole , N-Nitroso Caprolactam ,N-Nitroso Gabapentin EP Impurity A , N-Nitroso Rizatriptan , N-Nitroso Zolmitriptan, N-Nitroso Naratriptan , N-Nitroso Tadalafil , N-Nitroso Eletriptan etc. are ready Stock
search icon
We are thrilled to announce that the highly anticipated N-Nitroso impurities of Amide and Indole have now been successfully developed e.g. N-Nitroso Orlistat , N-Nitroso Ropinirole , N-Nitroso Caprolactam ,N-Nitroso Gabapentin EP Impurity A , N-Nitroso Rizatriptan , N-Nitroso Zolmitriptan, N-Nitroso Naratriptan , N-Nitroso Tadalafil , N-Nitroso Eletriptan etc. are ready Stock

Menu

Nitroso

Nitrosamines are a group of chemical compounds that contain the nitroso functional group (NO) attached to an amine group (-NH). They can form in various ways, including through industrial processes, combustion, and certain chemical reactions, particularly involving nitrites and secondary amines. Nitrosamines are of concern because Many nitrosamines (N-Nitrosamines) are potent genotoxins; some have been classified as possible human carcinogens, although the degree of risk can vary depending on factors such as the amount of exposure and individual susceptibility. Synchemia Research Chemical is dedicated to thoroughly investigating the formation of nitroso impurities in APIs, including those related to the manufacturing processes. This approach indicates a proactive stance toward quality control and regulatory compliance. By exploring all potential sources of nitroso impurities, including those arising from the production processes themselves, Synchemia Research Chemical demonstrates a commitment to ensuring the purity, safety, and efficacy of their pharmaceutical products. Nitrosoamines, including N-Des-methyl Nitroso impurities, are important in pharmaceutical research and development due to their potential impact on drug safety and efficacy. Understanding and controlling the presence of these impurities is crucial for ensuring the quality and safety of pharmaceutical products. Can N-Nitrosamines exist in two different stable forms? N-nitrosamines substituted with two different alkyl groups can exist in two different stable forms distinguishable by several analytical methods. The two rotamers may differ in their overall dipole moment and therefore may posses different chemical and physical properties. Why do I see two peaks when analyzing N-Nitrosamines by HPLC or GC? HPLC and GC)analysis of N-nitrosamines may show two rotamers of the N-nitrosamine as two separate peaks. Whether two peaks are observed depends on the structure of the N-nitrosamine (i.e., symmetric vs. asymmetric) as well as the separation power of the analytical method.
We are the Synchemia Research Chemical specializes in manufacturing and exporting various nitrosoamine compounds, particularly focusing on N-Des-methyl Nitroso impurities of various APIs and nitroso compounds of direct APIs that contain secondary amines. By specializing in the synthesis and export of these compounds, Synchemia Research likely plays a significant role in supporting the pharmaceutical industry's efforts to meet regulatory requirements and ensure the highest standards of quality and safety in drug manufacturing.
download image Download catalogue

Pharmaceutical Reference Standards

Praziquantel Nitroso Impurity 2 - D4
Praziquantel Nitroso Impurity 2 - D4
CAT No SRC-N0143731
CAS No NA
Mol.F. C11H12D4N2O3
Mol.Wt. 228.3 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Phenylephrine D3
N-Nitroso Phenylephrine D3
CAT No SRC-N0143732
CAS No NA
Mol.F. C9H9D3N2O3
Mol.Wt. 199.2 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Desmethyl Pimavanserin
N-Nitroso Desmethyl Pimavanserin
CAT No SRC-N0143733
CAS No NA
Mol.F. C24H31FN4O3
Mol.Wt. 442.5 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Di Vanillyl Amine
N-Nitroso Di Vanillyl Amine
CAT No SRC-N0143734
CAS No NA
Mol.F. C16H18N2O5
Mol.Wt. 318.3 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Perhexiline
N-Nitroso Perhexiline
CAT No SRC-N0143735
CAS No NA
Mol.F. C19H34N2O
Mol.Wt. 306.5 g/mole
INV STATUS CUSTOM SYNTHESIS
N‐Nitroso Protriptyline
N‐Nitroso Protriptyline
CAT No SRC-N0143736
CAS No NA
Mol.F. C19H20N2O
Mol.Wt. 292.4 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Pendimethalin
N-Nitroso Pendimethalin
CAT No SRC-N0143737
CAS No 68897-50-7
Mol.F. C13H18N4O5
Mol.Wt. 310.3 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Pseudoephedrine D3
N-Nitroso Pseudoephedrine D3
CAT No SRC-N0143738
CAS No NA
Mol.F. C10H11D3N2O2
Mol.Wt. 197.3 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso N-Desmethyl Pizotifen
N-Nitroso N-Desmethyl Pizotifen
CAT No SRC-N0143739
CAS No NA
Mol.F. C18H18N2OS
Mol.Wt. 310.4g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Pyronaridine
N-Nitroso Pyronaridine
CAT No SRC-N0143740
CAS No NA
Mol.F. C29H31ClN6O3
Mol.Wt. 547.1g/mole
INV STATUS CUSTOM SYNTHESIS
Pyronaridine Nitroso Impurity 1 Lithium Salt
Pyronaridine Nitroso Impurity 1 Lithium Salt
CAT No SRC-N0143741
CAS No NA
Mol.F. C13H10ClN3O4 : Li
Mol.Wt. 307.7 : 6.9g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso-N-methyl-N-tetradecylamine
N-Nitroso-N-methyl-N-tetradecylamine
CAT No SRC-N0143742
CAS No 75881-20-8
Mol.F. C15H32N2O
Mol.Wt. 256.4 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso-3-Hydroxypiperidine
N-Nitroso-3-Hydroxypiperidine
CAT No SRC-N0143743
CAS No 55556-85-9
Mol.F. C5H10N2O2
Mol.Wt. 130.1 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso 4-Hydroxy-L-proline
N-Nitroso 4-Hydroxy-L-proline
CAT No SRC-N0143744
CAS No 2308465-20-3
Mol.F. C5H8N2O4
Mol.Wt. 160.1 g/mole
INV STATUS CUSTOM SYNTHESIS
N,N′-Dibutyl-N′-nitrosourea
N,N′-Dibutyl-N′-nitrosourea
CAT No SRC-N0143745
CAS No 56654-52-5
Mol.F. C9H19N3O2
Mol.Wt. 201.3 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Ethyl-N-nitrosourethane
N-Ethyl-N-nitrosourethane
CAT No SRC-N0143746
CAS No 614-95-9
Mol.F. C5H10N2O3
Mol.Wt. 146.1 g/mole
INV STATUS CUSTOM SYNTHESIS

Let’s advance your research together.

Partner with us for specialized chemical materials and synthesis services that enable pharmaceutical innovation.